Table 2.
Overall response, best overall response, and duration to maximum tumor shrinkage.
| All n = 289 (%) |
GC n = 148 (%) |
GS n = 141 (%) |
|
|---|---|---|---|
| Overall response at 6 weeks | |||
| CR | 0 | 0 | 0 |
| PR | 43 (14.9) | 21 (14.2) | 22 (15.6) |
| SD | 201 (69.6) | 102 (68.9) | 99 (70.2) |
| PD | 37 (12.8) | 20 (13.5) | 17 (12.1) |
| NE | 3 (1.0) | 2 (1.4) | 1 (0.7) |
| Missing data | 5 (1.7) | 3 (2.0) | 2 (1.4) |
| Best overall response | |||
| CR | 2 (0.7) | 0 | 2 (1.4) |
| PR | 88 (30.4) | 48 (32.4) | 40 (28.4) |
| SD | 150 (51.9) | 74 (50.0) | 76 (53.9) |
| PD | 40 (13.8) | 21 (14.2) | 19 (13.5) |
| NE | 9 (3.1) | 5 (3.4) | 4 (2.8) |
| Duration to maximum tumor shrinkage | |||
| 6 weeks | 132 (45.7) | 64 (43.2) | 68 (48.2) |
| 12 weeks | 61 (21.1) | 28 (18.9) | 33 (23.4) |
| 18 weeks | 48 (16.6) | 28 (18.9) | 20 (14.2) |
| 24 weeks | 48 (16.6) | 28 (18.9) | 20 (14.2) |
Abbreviations: GC: gemcitabine plus cisplatin; GS: gemcitabine plus S-1; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluated.